TrialThe New England journal of medicine2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5,164 papers cite itlatest 60 shown
this paperpooled ittrialcites it